Directors Dealings
Director dealings are proprietary transactions by executives, which are reportable under Art. 19 MAR. The publication of these transactions is an important contribution to the prevention of insider dealing and market manipulation. In addition, knowledge of such transactions is of great importance to the market, as these transactions provide indications of management's assessment of the company's future business prospects. The information presented here relates to companies that are under the supervision of BaFin.
MorphoSys AG: A reportable insider transaction was published on 9th October 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 9th October 2023,
The Insider Transaction was made by Vermeylen, Krisja 
. The transaction toke place on 6th October 2023. The order was executed at the trading place Morgan Stanley Europe S.E. systematic internaliser. . The aggregated volume was 23.530,00 EUR, based on an average price of 23,53 EUR. The nature of the Investment was Buy.
MorphoSys AG: A reportable insider transaction was published on 20th September 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th September 2023,
The Insider Transaction was made by Cluzel, Dr. Marc . The transaction toke place on 18th September 2023. The order was executed at the trading place Xetra. . The aggregated volume was 775,25 EUR, based on an average price of 31,01 EUR. The nature of the Investment was Buy.
MorphoSys AG: A reportable insider transaction was published on 7th June 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 7th June 2023,
The Insider Transaction was made by Cluzel, Dr. Marc . The transaction toke place on 6th June 2023. The order was executed at the trading place Xetra. . The aggregated volume was 52.800,00 EUR, based on an average price of 26,40 EUR. The nature of the Investment was Buy.
MorphoSys AG: A reportable insider transaction was published on 6th June 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 6th June 2023,
The Insider Transaction was made by Cluzel, Dr. Marc . The transaction toke place on 2nd June 2023. The order was executed at the trading place Xetra. . The aggregated volume was 24.280,00 EUR, based on an average price of 24,28 EUR. The nature of the Investment was Buy.
MorphoSys AG: A reportable insider transaction was published on 23rd May 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 23rd May 2023,
The Insider Transaction was made by Cluzel, Dr. Marc . The transaction toke place on 18th May 2023. The order was executed at the trading place Xetra. . The aggregated volume was 22.670,00 EUR, based on an average price of 22,67 EUR. The nature of the Investment was Buy.
MorphoSys AG: A reportable insider transaction was published on 28th November 2022. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 28th November 2022,
The Insider Transaction was made by Vermeylen, Krisja . The transaction toke place on 23rd November 2022. The order was executed at the trading place XTX Markets SAS. . The aggregated volume was 14.860,00 EUR, based on an average price of 14,86 EUR. The nature of the Investment was Buy.
MorphoSys AG: A reportable insider transaction was published on 21st November 2022. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 21st November 2022,
The Insider Transaction was made by Cluzel, Dr. Marc . The transaction toke place on 17th November 2022. The order was executed at the trading place Xetra. . The aggregated volume was 29.922,20 EUR, based on an average price of 14,96 EUR. The nature of the Investment was Buy.
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Equity Story | 176 | 27th August 2024 | EQS Group AG | EQS |
| Corporate Research | 0 | - | - | Corporate Research |
| Short Seller (DE) | 39 | 27th August 2024 | Qube Research & Technologies Limited | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.